Thymosin Alpha-1 Dosage as Reported in the Research Literature

The gist

This page describes Thymosin Alpha-1 dosage the way the studies report it — what was given, to whom, and how — and nothing more. It is not a how-to and contains no instructions for personal use. Across the clinical literature, the synthetic drug was almost always given as a small subcutaneous (under-the-skin) injection. The most common regimen in chronic hepatitis B trials was 1.6 mg twice a week. Single doses studied ranged from 0.8 to 6.4 mg. Sepsis and COVID-19 trials used more frequent dosing over short stretches. The peptide clears quickly — its half-life (the time for blood levels to fall by half) is roughly two hours, with levels returning toward baseline within about a day. None of this is a dose for any person; it is a record of how researchers ran their studies, written in the third person and tied to the population and route used.

Thymosin alpha 1 dosage

Thymosin alpha 1 dosage in the research literature centers on a small subcutaneous injection. A comprehensive review reports the standard single subcutaneous dose ranging from 0.8 to 6.4 mg, with multiple-dose regimens of 1.6 to 16 mg over five to seven days, and notes that the synthetic peptide thymalfasin is approved in more than 35 countries ^[4]. The most frequently studied chronic-treatment regimen is 1.6 mg subcutaneous twice weekly — the schedule used in the chronic hepatitis B and immune-reconstitution literature ^[8][13]. These figures are reported as studied doses in defined populations, not as recommendations: no human dose is endorsed anywhere on this site.

Doses studied, by setting and route

The dose schedule varied with the clinical setting:

• Chronic hepatitis B/C: 1.6 mg subcutaneous twice weekly — the standard chronic regimen ^[13].
• HIV immune reconstitution: 1.6 mg subcutaneous twice weekly for 12 weeks in the CD4 pilot study ^[8].
• Sepsis (ETASS, TESTS): 1.6 mg subcutaneous every 12 hours for 5–7 days ^[2][3].
• COVID-19 cohorts: 1.6 mg subcutaneous daily ^[6].
• Cancer adjuvant protocols: 1.6 mg subcutaneous twice weekly in combination regimens ^[7].

The subcutaneous route was used in essentially all clinical trials; in vitro/ex vivo and murine routes appear only in mechanistic work ^[5]. Every value here is reported as "studied at X mg in [population] by [route]" — research data, not instruction.

Thymosin alpha 1 injection

Thymosin alpha 1 injection in studies is subcutaneous — a small injection into the fat layer just under the skin. The peptide is supplied lyophilized (freeze-dried) and reconstituted before use; it is highly acidic (isoelectric point around 4.2), does not bind plasma proteins extensively, and is degraded by tissue and circulating aminopeptidases. Its N-terminal acetylation is required for activity. In documented clinical use the injection is generally well tolerated, with mild injection-site reactions the most common complaint ^[4]. This is a description of how the injection was administered in research, not a procedure to follow.

Half-life and pharmacokinetics

Thymosin Alpha-1 clears quickly. After subcutaneous injection in human volunteers, the elimination half-life is approximately two hours, with peak blood levels (Tmax) at roughly one to two hours and levels returning toward baseline within about 24 hours; its volume of distribution is consistent with distribution into extracellular fluid. The short systemic half-life sits oddly against durable immune effects, which researchers attribute to the peptide's role as a biological-response modifier — it triggers downstream immune programs that outlast its own presence in blood, rather than acting like a sustained-occupancy drug.

Why the dose looks the same across very different diseases

One striking feature of the literature is how little the per-injection dose varies. Whether the setting is chronic hepatitis B, HIV immune reconstitution, sepsis, COVID-19, or cancer support, the unit dose clusters tightly around 1.6 mg subcutaneous — what changes between settings is the frequency and duration, not the amount per shot ^[4]. In chronic, slow-burn indications the schedule is twice weekly for months ^[13]; in acute critical-illness settings it compresses to every 12 hours or once daily for a short course ^[2][3][6]. This pattern reflects the peptide's mechanism: as a biological-response modifier it sets immune programs in motion rather than maintaining a blood concentration, so dose intensity is governed by how often the immune system is being prompted, not by sustained drug exposure. None of this is guidance for personal use; it is a description of how trial protocols were structured.

Formulation, reconstitution, and stability as studied

The synthetic peptide is supplied lyophilized (freeze-dried) and reconstituted into solution before subcutaneous administration in trials. Its physical chemistry shapes how it is handled: it is highly acidic (isoelectric point around 4.2), carries no aromatic residues and no disulfide bonds, and does not bind plasma proteins extensively, so it stays in solution readily but is also rapidly degraded by tissue and circulating aminopeptidases — enzymes that chew peptides apart — which is consistent with the short half-life ^[4]. The N-terminal acetyl cap is required for biological activity, so an intact, correctly synthesized molecule matters. Community concerns about underdosed or misidentified research-grade material map directly onto these properties: without regulated quality control, there is no assurance the vial contains the intact, correctly acetylated 28-amino-acid peptide at the labeled amount.